Activity Description

Neurofibromatosis type 1 (NF-1) is a rare autosomal dominant disorder of the nervous system that is associated with significant morbidity, including cutaneous and plexiform neurofibromas, optic pathway gliomas, skin pigmentation, bone deformities, neurocognitive deficits, and an increased risk of several types of cancer.

In this educational on-demand activity, an expert panel provides insights into the expanding landscape of targeted therapies and discusses optimal clinical decision-making for patients with NF-1 and NF-1─related plexiform neurofibromas based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration.

Target Audience

This activity has been designed to meet the educational needs of pediatric hematologists and oncologists, pediatric hematology/oncology nurses, allied healthcare professionals, and other clinicians involved in the care of patients with NF-1 and NF-1–related PNs.

Educational Objectives

Upon completion of this activity, participants will be able to:

• Describe the genetic etiology, diverse clinical symptomatology, and diagnostic characteristics of neurofibromatosis type 1 (NF-1)
• Review the current treatment landscape and unmet needs for patients with plexiform neurofibromas and other NF-1–associated tumors
• Evaluate the rationale for MEK inhibitors and other novel targeted therapies in clinical development for the treatment of NF-1–related benign and malignant tumors (eg, plexiform neurofibromas, optic pathway gliomas, malignant peripheral nerve sheath tumors)
• Summarize recent evidence on the benefits and risks of MEK inhibitors and other emerging targeted therapy options for the management of NF-1–related plexiform neurofibromas and other tumors in pediatric and adult patients
• Incorporate MEK inhibitors into treatment plans for patients with NF-1–related plexiform neurofibromas and other tumors, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and coordination of care

Providership, Credit, and Support

This CME/CNE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by an independent educational grant from AstraZeneca.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

Medical Learning Institute, Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Successful completion of this continuing nursing education activity will be awarded 1.25 contact hour(s).

Faculty Disclosures

Co-Chair
Concetta (Connie) DiDomenico, RN, MSN, PNP-BC, CPHON
Neuro-Oncology Nurse Practitioner
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania

Concetta (Connie) DiDomenico, RN, MSN, PNP-BC, CPHON, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair
Michael J. Fisher, MD
Chief, Neuro-Oncology Section
Director, Neurofibromatosis Program
Hubert J.P. and Anne Faulkner Schoemaker Endowed Chair in Pediatric Neuro-Oncology
Center for Childhood Cancer Research and Division of Oncology
The Children's Hospital of Philadelphia
Professor of Pediatrics
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Michael J. Fisher, MD, has no financial interests/relationships or affiliations in relation to this activity.

Faculty
Andrea Rennie, RN, BSN
Nurse Navigator
Neurofibromatosis Program
The Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Andrea Rennie, RN, BSN, has no financial interests/relationships or affiliations in relation to this activity.

Katherine A. Smith, MPH, BSN, RN, CPN, CHES
Clinical Research Nurse II
Pediatric Neuro-Oncology & Neurofibromatosis Program
The Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Katherine A. Smith, MPH, BSN, RN, CPN, CHES, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca.

Planning Committee Disclosures

Tracy L. Greene, MSN, RN, FNP-C, Nurse Planner, MLI, has nothing to disclose.

The planners from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Natalie I. Vokes, MD
Amita B. Patel, MSN, RN, AOCNP, NP-C

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CNE credit. There are no prerequisites and there is no fee to participate in this activity or to receive CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/CNE Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView